TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors

Stopped Tarus is conducting clinical development under a single IND, specifically IND for TT-10 (PORT-6). Tarus has withdrawn Study TT-4-101 under the TT-4 IND; however the TT-4 IND will remain active.

Conditions

• Colorectal Cancer
• Gastric Cancer
• Hepatocellular Carcinoma
• Pancreatic Cancer

Interventions

• DRUG: TT-4

Sponsor

Tarus Therapeutics, Inc.